Spinogenix Completes Enrollment in Phase 2 Trial of Tazbentetol for Schizophrenia Treatment
核心洞察
Spinogenix (搜索) has completed patient enrollment in its Phase 2 clinical trial of tazbentetol (搜索), a first-in-class synaptic regenerative therapy for schizophrenia (搜索) treatment.
The randomized, double-blind, placebo-controlled trial enrolled 32 adult patients who will receive daily oral doses for six weeks to evaluate safety and efficacy.
Tazbentetol (搜索) aims to address all three symptom domains of schizophrenia (搜索), including positive, negative, and cognitive symptoms that current antipsychotics largely leave untreated.
Spinogenix (搜索), a clinical-stage biopharmaceutical company, has completed patient enrollment in its Phase 2 clinical trial evaluating tazbentetol (搜索) (formerly SPG302) for schizophrenia (搜索) treatment. The milestone represents a significant step forward for the first-in-class synaptic regenerative therapy designed to address multiple symptom domains of the complex psychiatric disorder.
The randomized, double-blind, placebo-controlled trial (NCT06442462) enrolled 32 adult patients diagnosed with schizophrenia (搜索). Participants will receive daily oral doses of either tazbentetol (搜索) or placebo for six weeks while researchers evaluate the therapy's safety, efficacy, tolerability, and pharmacodynamics.
Novel Mechanism Targets Synaptic Regeneration
Tazbentetol (搜索) represents a paradigm shift in schizophrenia (搜索) treatment by focusing on synaptic regeneration rather than traditional symptom management. The investigational therapy is designed to trigger neurons to produce new glutamatergic synapses (搜索), potentially restoring cognitive, motor, and other functions that have been compromised by the disease.
"Attaining full enrollment in this Phase 2 trial is a critical step in our mission to offer a new treatment option for the millions of people living with schizophrenia (搜索)," said Dr. Stella Sarraf, CEO and Founder of Spinogenix (搜索). "We are excited to complete this trial designed to establish the potential of a synaptic regenerative therapy to address the positive symptoms of schizophrenia, and to improve negative and cognitive symptoms that remain largely unaddressed by standard of care medications."
Addressing Unmet Medical Needs
Schizophrenia (搜索) is characterized by three distinct symptom domains: positive symptoms including hallucinations and delusions, negative symptoms such as social withdrawal and lack of motivation, and cognitive symptoms involving memory, attention, and language deficits. Current antipsychotic medications primarily manage positive symptoms effectively, leaving negative and cognitive symptoms largely untreated.
Dr. David Walling, Chief Clinical Officer at CenExel (搜索) and Principal Investigator of the trial, emphasized the potential significance of tazbentetol (搜索)'s novel approach. "Tazbentetol brings a potentially important new mechanism of action to the field and has the potential to shift the treatment paradigm towards regenerative medicine, in essence bringing back a key component of what has been lost at a structural level in the disease - synapses," he said.
Comprehensive Assessment Strategy
The trial employs multiple assessment tools to evaluate tazbentetol (搜索)'s therapeutic potential. Primary and secondary endpoints include changes in symptom severity measured by the Positive and Negative Syndrome Scale (PANSS) score and improvements in the Clinical Global Impression of Improvement (CGI-I).
The study integrates electroencephalogram (EEG) analysis as an objective neurophysiological biomarker sensitive to synaptic density. Changes in schizophrenia (搜索)-related EEG abnormalities at rest and in response to stimuli provide valuable insights into the therapy's pharmacodynamic activity. Additionally, researchers are using the MATRICS Consensus Cognitive Battery (MCCB) to evaluate improvements in cognitive functioning through timed assessments.
Upcoming Data Presentation
Spinogenix (搜索) plans to present interim results from the trial at the Schizophrenia (搜索) International Research Society (SIRS) 2026 Annual Congress in Florence, Italy, scheduled for March 26-29, 2026. The presentation will provide the first clinical data on tazbentetol (搜索)'s performance in schizophrenia patients.
Broader Development Pipeline
Beyond schizophrenia (搜索), Spinogenix (搜索) is developing tazbentetol (搜索) for multiple neurological conditions, including ALS (搜索) and Alzheimer's disease (搜索). The company has received FDA and EMA Orphan Drug designations for ALS, highlighting the therapy's potential across neurodegenerative disorders.
In February 2025, Spinogenix (搜索) reported topline outcomes from a Phase 2 trial of SPG601, another investigational therapy in its pipeline, for treating Fragile X syndrome (搜索) in adult male patients. That randomized, placebo-controlled study compared a single dose of SPG601 with placebo in ten adult men with core attributes of the genetic disorder.